Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus standard-dose rituximab for relapse prevention in acquired TTP
2017-001117-86Phase 4Unknown
- Sponsor
- University College London
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of rituximab in thrombotic thrombocytopenic purpura (TTP) (2 arms), sponsored by University College London. Primary endpoint: Time to retreatment with rituximab or other immunosuppression. Status: unknown.
02
Drugs
rituximab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on 2017-001117-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001117-86.